Blood Cancer United Acquires Investigational Drug Supply to Preserve Access for Children with Rare, Fatal Leukemia
Read Original Source
Aspen Peck with her parents, Ashley and Troy. Blood Cancer United First-of-its-kind nonprofit intervention enables continued compassionate use of a promising treatment for children facing a 15% to 30% survival rate WASHINGTON, June 11, 2026 /PRNewswire/ -- In an unprecedented intervention, Blood Cancer United announced that it has acquired the remaining supply of a promising investigational therapy to keep it available for children with an ultra-rare and frequently fatal form of acute myeloid leukemia (AML).
AI Summary
Main Idea: Blood Cancer United bought the remaining supply of an investigational leukemia drug to keep it available for children with a rare and often deadly form of AML.
Key Points:
- The drug, luveltamab tazevibulin, had early promise for CBFA2T3-GLIS2-rearranged AML, a rare childhood cancer with a survival rate of about 15% to 30%.
- Blood Cancer United said it acquired the supply and rights to provide the drug through the FDA’s compassionate use pathway at no cost to patients.
- The group said the move is meant to prevent a promising treatment from disappearing because of commercial and development issues.
- The effort is being supported by Blood Cancer United’s Dare to Dream project and a gift from The Andrew McDonough B+ Foundation, with one child patient cited as an example of the drug’s impact.
Impact on the People
Negative Impact
Drug access depends on a small, leftover supply, so some families may still face delays or no treatment if more children need it.
Positive Impact
Blood Cancer United and the B+ Foundation preserved no-cost access to a promising leukemia therapy for a few very sick children, which could save lives and ease family.
How did each entity affect people?
Rate how each entity in this article affected the American people.
- Primary:Blood Cancer Unitednonprofit / NGO
Candidate Entities9 candidates · 5 weighted vote min · 70% decision
- Blood Cancer Unitednonprofit / NGOPrimaryEvaluated
Primary organization in the story; it acquired the remaining drug supply and is preserving compassionate access for children.
Include 0 (0%)Ignore 0 (0%)5 to threshold - Aspen PeckpersonMajorAI selected
Child patient whose case illustrates the article’s central access story.
Include 0 (0%)Ignore 0 (0%)5 to threshold - E. Anders Kolb, M.D.personMajorAI selected
Blood Cancer United president and CEO quoted as explaining the organization’s intervention and rationale.
Include 0 (0%)Ignore 0 (0%)5 to threshold - Gwen Nichols, M.D.personMajorAI selected
Blood Cancer United chief medical officer quoted on the medical importance of preserving access.
Include 0 (0%)Ignore 0 (0%)5 to threshold - The Andrew McDonough B+ Foundationnonprofit / NGOMajorAI selected
Named funding partner supporting the effort to preserve access to the treatment.
Include 0 (0%)Ignore 0 (0%)5 to threshold - Food and Drug Administrationgovernment agency or bodyContextCandidate
Mentioned as the agency whose compassionate use pathway enabled access to the investigational therapy.
Include 0 (0%)Ignore 0 (0%)5 to threshold - Troy PeckpersonContextCandidate
Aspen Peck’s father, quoted as a family representative describing the treatment’s impact.
Include 0 (0%)Ignore 0 (0%)5 to threshold
Comments 0
Comments here are the same thread shown when this article appears in The Pulse.
No comments on this article yet.
Sign in to comment